23andMe Adds Ten Genetic Risk Reports

Yesterday I received this announcement from 23andMe:

I am happy to announce that the U.S. Food and Drug Administration (FDA) granted 23andMe authorization to market ten direct-to-consumer, genetic health risk reports. This new category of health reports will provide customers with information about genetic variants that could increase their risk for certain diseases.

The authorization includes reports on Late-Onset Alzheimer’s Disease, Parkinson’s Disease, Celiac Disease and Hereditary Thrombophilia as well as six additional conditions. To learn more about these reports and the additional reports covered in the authorization, you can refer to the FDA’s press release or our blog.

I am proud to say we are the first and only company to receive FDA authorization to market genetic health risk reports without a prescription. It’s a defining moment – giving individuals direct access to more information about how their DNA could impact their health.

The first set of new genetic health risk reports to be released in the U.S. will include Late-Onset Alzheimer’s Disease, Parkinson’s Disease, Hereditary Thrombophilia, Alpha-1 Antitrypsin Deficiency, and a new carrier status report for Gaucher’s Disease. These will be available by the end of April with additional reports to follow. Look for an email in the next few weeks about your eligibility to receive these reports.

Anne Wojcicki
CEO and Co-Founder

From the press release, the health conditions are as follows:

I am most intrigued by the late-onset Alzheimer’s results.  Intriguing development, and a reason to consider 23andMe if you are interested in the results of these tests.

Posted in DNA

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s